A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients

Item

http://www.wikidata.org/entity/Q35793176

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients

@ast

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients

@en

type

Item

label

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients

@ast

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients

@en

prefLabel

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients

@ast

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients

@en

P1476

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients

@en

P2093

Brenda W Cooper

http://www.w3.org/2001/XMLSchema#string

Mehdi Hamadani

http://www.w3.org/2001/XMLSchema#string

Michael D Craig

http://www.w3.org/2001/XMLSchema#string

Richard J Creger

http://www.w3.org/2001/XMLSchema#string

Tamila L Kindwall-Keller

http://www.w3.org/2001/XMLSchema#string

William W Tse

http://www.w3.org/2001/XMLSchema#string

P2860

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

Age and acute myeloid leukemia.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.

P304

428-432.e2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLML.2015.02.017

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hillard M Lazarus

P577

2015-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25776192

http://www.w3.org/2001/XMLSchema#string

P932

4484305

http://www.w3.org/2001/XMLSchema#string